Christine De Wolf‐Peeters

Prognostic Value of Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([¹⁸F]FDG) After First-Line Chemotherapy in Non-Hodgkin’s Lymphoma: Is [¹⁸F]FDG-PET a Valid Alternative to Conventional Diagnostic Methods?

Karoline Spaepen, Sigrid Stroobants, Patrick Dupont et al. · Journal of Clinical Oncology · 2001 · 466 citations

Medicine, Nuclear Medicine, Oncology +17

Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation

Karoline Spaepen, Sigrid Stroobants, Patrick Dupont et al. · Blood · 2003 · 225 citations

Medicine, Nuclear Medicine, Oncology +14

Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma

Roberto Chiarle, Leo M. Budel, Jeffrey Skolnik et al. · Blood · 2000 · 218 citations

Life Sciences, Cell Biology, Oncology +16

[18F]FDG PET monitoring of tumour response to chemotherapy: does [18F]FDG uptake correlate with the viable tumour cell fraction?

Karoline Spaepen, Sigrid Stroobants, Patrick Dupont et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2003 · 195 citations

Medicine, Nuclear Medicine, Oncology +14

Can positron emission tomography with [¹⁸F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

Karoline Spaepen, Sigrid Stroobants, Patrick Dupont et al. · British Journal of Haematology · 2001 · 169 citations · Full text

Medicine, Nuclear Medicine, Oncology +17